FindTrial
Sign In

HDAC2 deficiency promotes glucocorticoid resistance in the treatment of acute respiratory distress syndrome and the sensitizing effect of theophylline supplementation

HDAC2 deficiency promotes glucocorticoid resistance in the treatment of acute respiratory distress syndrome and the sensitizing effect of theophylline supplementation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110999
Enrollment
Unknown
Registered
2025-10-23
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Interventions

ARDS group receiving glucocorticoid therapy:None

Sponsors

Shengli Oilfield Central Hospita
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Adult hospitalized patients aged >= 18 years old; According to the Berlin definition, patients with moderate to severe ARDS; The informed consent form has been signed.

Exclusion criteria

Exclusion criteria: Pregnancy; Uncontrolled diabetes and hypertension; Contraindications for the use of glucocorticoids; Not actively seeking treatment.

Design outcomes

Primary

MeasureTime frame
HDAC2;GRa mRNA;GRß mRNA;NF-?B mRNA;—

Secondary

MeasureTime frame
White blood cell count;Percentage of neutrophils;C-reactive protein;Procalcitonin;Interleukin-6;Arterial blood gas;—

Countries

China

Contacts

Public ContactHong Shukun

Shengli Oilfield Central Hospital

hongshukun@126.com+86 546 877 9023

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026